Clinical Implications of Size of Cavities in Patients With Nontuberculous Mycobacterial Pulmonary Disease: A Single-Center Cohort Study

Abstract Background The presence of cavities is associated with unfavorable prognosis in patients with nontuberculous mycobacterial pulmonary disease (NTM-PD). However, little is known about the characteristics of such cavities and their impact on clinical outcomes. The aim of this study was to investigate the size of cavities and their implications on treatment outcomes and mortality in patients with NTM-PD. Methods We included patients diagnosed with NTM-PD at Seoul National University Hospital between January 1, 2007, and December 31, 2018. We measured the size of cavities on chest computed tomography scans performed at the time of diagnosis and used multivariable logistic regression and Cox proportional hazards regression analysis to investigate the impact of these measurements on treatment outcomes and mortality. Results The study cohort comprised 421 patients (noncavitary, n = 329; cavitary, n = 92) with NTM-PD. During a median follow-up period of 49 months, 118 (35.9%) of the 329 patients with noncavitary and 64 (69.6%) of the 92 patients with cavitary NTM-PD received antibiotic treatment. Cavities >2 cm were associated with worse treatment outcomes (adjusted odds ratio, 0.41; 95% CI, 0.17–0.96) and higher mortality (adjusted hazard ratio, 2.52; 95% CI, 1.09–5.84), while there was no difference in treatment outcomes or mortality between patients with cavities ≤2 cm and patients with noncavitary NTM-PD. Conclusions Clinical outcomes are different according to the size of cavities in patients with cavitary NTM-PD; thus, the measurement of the size of cavities could help in making clinical decisions.

[1]  J. Brożek,et al.  Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline. , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[2]  J. Yim,et al.  BACES Score for Predicting Mortality in Nontuberculous Mycobacterial Pulmonary Disease. , 2020, American journal of respiratory and critical care medicine.

[3]  J. Brożek,et al.  Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline , 2020, European Respiratory Journal.

[4]  J. Yim,et al.  Longitudinal changes in health-related quality of life according to clinical course among patients with non-tuberculous mycobacterial pulmonary disease: a prospective cohort study , 2020, BMC Pulmonary Medicine.

[5]  H. Kida,et al.  Characteristic chest CT findings for progressive cavities in Mycobacterium avium complex pulmonary disease: a retrospective cohort study , 2020, Respiratory Research.

[6]  K. Carriere,et al.  Prognostic factors associated with long-term mortality in 1445 patients with nontuberculous mycobacterial pulmonary disease: a 15-year follow-up study , 2019, European Respiratory Journal.

[7]  C. Ki,et al.  Long-term natural history of non-cavitary nodular bronchiectatic nontuberculous mycobacterial pulmonary disease. , 2019, Respiratory medicine.

[8]  T. Shim,et al.  Tuberculosis drugs’ distribution and emergence of resistance in patient’s lung lesions: A mechanistic model and tool for regimen and dose optimization , 2019, PLoS medicine.

[9]  T. Shim,et al.  The natural history of non-cavitary nodular bronchiectatic Mycobacterium avium complex lung disease. , 2019, Respiratory medicine.

[10]  W. Koh,et al.  Epidemiology of Nontuberculous Mycobacterial Infection, South Korea, 2007–2016 , 2019, Emerging infectious diseases.

[11]  S. Cooray,et al.  Global Epidemiology of NTM Disease (Except Northern America) , 2018, Nontuberculous Mycobacterial Disease.

[12]  T. Franquet,et al.  Cavitary Lung Diseases: A Clinical‐Radiologic Algorithmic Approach , 2018, Chest.

[13]  S. Holland,et al.  Treatment outcome definitions in nontuberculous mycobacterial pulmonary disease: an NTM-NET consensus statement , 2018, European Respiratory Journal.

[14]  C. Haworth,et al.  British Thoracic Society Guideline for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD) , 2017, BMJ Open Respiratory Research.

[15]  C. Ki,et al.  Outcomes of Mycobacterium avium complex lung disease based on clinical phenotype , 2017, European Respiratory Journal.

[16]  Mi Young Kim,et al.  Comparison of chest CT findings in nontuberculous mycobacterial diseases vs. Mycobacterium tuberculosis lung disease in HIV-negative patients with cavities , 2017, PloS one.

[17]  J. Yim,et al.  Progression and Treatment Outcomes of Lung Disease Caused by Mycobacterium abscessus and Mycobacterium massiliense , 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[18]  Satoshi Mitarai,et al.  Epidemiology of Pulmonary Nontuberculous Mycobacterial Disease, Japan , 2016, Emerging infectious diseases.

[19]  J. Falkinham Current Epidemiologic Trends of the Nontuberculous Mycobacteria (NTM) , 2016, Current Environmental Health Reports.

[20]  M. Tashiro,et al.  The risk factors for developing of chronic pulmonary aspergillosis in nontuberculous mycobacteria patients and clinical characteristics and outcomes in chronic pulmonary aspergillosis patients coinfected with nontuberculous mycobacteria. , 2016, Medical mycology.

[21]  K. Winthrop,et al.  Population-based Incidence of Pulmonary Nontuberculous Mycobacterial Disease in Oregon 2007 to 2012. , 2015, Annals of the American Thoracic Society.

[22]  O. Kwon,et al.  Clinical characteristics and treatment outcomes of chronic pulmonary aspergillosis. , 2013, Medical mycology.

[23]  K. Lee,et al.  Nodular bronchiectatic Mycobacterium avium complex pulmonary disease. Natural course on serial computed tomographic scans. , 2013, Annals of the American Thoracic Society.

[24]  T. Kanauchi,et al.  Prognostic factors of 634 HIV-negative patients with Mycobacterium avium complex lung disease. , 2012, American journal of respiratory and critical care medicine.

[25]  D. Raoult,et al.  rpoB sequence-based identification of Mycobacterium avium complex species. , 2008, Microbiology.

[26]  K. Chida,et al.  Mycobacterium avium complex disease: prognostic implication of high-resolution computed tomography findings , 2008, European Respiratory Journal.

[27]  J. Stout,et al.  Cavitary Pulmonary Disease , 2008, Clinical Microbiology Reviews.

[28]  N. Müller,et al.  Fleischner Society: glossary of terms for thoracic imaging. , 2008, Radiology.

[29]  N. Pace,et al.  Interpretive criteria for identification of bacteria and fungi by DNA target sequencing; approved guideline , 2008 .

[30]  Robert Horsburgh,et al.  An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. , 2007, American journal of respiratory and critical care medicine.

[31]  M. Chung,et al.  Hypothesis on the evolution of cavitary lesions in nontuberculous mycobacterial pulmonary infection: thin-section CT and histopathologic correlation. , 2005, AJR. American journal of roentgenology.

[32]  Yoon-Hoh Kook,et al.  Identification of Mycobacterial Species by Comparative Sequence Analysis of the RNA Polymerase Gene (rpoB) , 1999, Journal of Clinical Microbiology.